3rd RAS/MAPK Pathway Targeted Drug Discovery Summit
Evvnt Promotion / evvnt
Archivo
22.02.2022 - 24.02.2022 Online, USA
Time: 9:00 AM - 3:30 PM
Temas de la conferencia
For decades, RAS proteins have been considered “undruggable.” This all changed following the recent approval of the first-ever targeted KRAS G12C therapy, marking a major landmark for this community. This breakthrough has certainly laid out a roadmap for future success, with more investment and innovation in the field than ever before, particularly within emerging discovery strategies being pursued by the biopharma industry.
For decades, RAS proteins have been considered “undruggable.” This all changed following the recent approval of the first-ever targeted KRAS G12C therapy, marking a major landmark for this community. This breakthrough has certainly laid out a roadmap for future success, with more investment and innovation in the field than ever before, particularly within emerging discovery strategies being pursued by the biopharma industry.
Organizador profesional (PCO)
Hanson Wade
Hanson Wade
Información e inscripción:
https://go.evvnt.com/913421-2?pid=4832
Ms. Georgina FitzGerald
Medicina General
Cantacto organizador
83 Great Titchfield Street
W1W 6RH London
United Kingdom
83 Great Titchfield Street
W1W 6RH London
United Kingdom
"Going International fomenta el acceso a la educación y a la formación continua independientemente de fronteras sociales, geográficas y nacionales."
